Medicenna Therapeutics (MDNA) Insider Trading & Ownership C$0.84 0.00 (0.00%) As of 08/1/2025 03:59 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock Medicenna Therapeutics (TSE:MDNA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage22.57%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)C$29.65KNumber OfInsiders Selling(Last 12 Months)0 Get MDNA Insider Trade Alerts Want to know when executives and insiders are buying or selling Medicenna Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MDNA Insider Buying and Selling by Quarter Medicenna Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/13/2025Albert George BeraldoDirectorBuy500C$1.29C$645.001/9/2025David HymanSenior OfficerBuy20,000C$1.45C$29,000.00 (Data available from 1/1/2013 forward) MDNA Insider Trading Activity - Frequently Asked Questions Who is on Medicenna Therapeutics' Insider Roster? The list of insiders at Medicenna Therapeutics includes Albert George Beraldo, Chandra Panchal, and David Hyman. Learn more on insiders at MDNA. What percentage of Medicenna Therapeutics stock is owned by insiders? 22.57% of Medicenna Therapeutics stock is owned by insiders. Learn more on MDNA's insider holdings. Which Medicenna Therapeutics insiders have been buying company stock? The following insiders have purchased MDNA shares in the last 24 months: Albert George Beraldo (C$645.00), and David Hyman (C$29,000.00). How much insider buying is happening at Medicenna Therapeutics? Insiders have purchased a total of 20,500 MDNA shares in the last 24 months for a total of C$29,645.00 bought. Medicenna Therapeutics Key ExecutivesDr. Fahar Merchant Ph.D. (Age 67)Founder, Chairman, President & CEO Compensation: $454.37kMs. Rosemina Merchant B.Sc. (Age 67)M.E.Sc, Founder & Chief Development Officer Compensation: $364.46kMr. David Hyman CA (Age 51)CBV, Chief Financial Officer Dr. Samuel R. Denmeade M.D.Scientific Advisor More Insider Trading Tools from MarketBeat Related Companies Fennec Pharmaceuticals Insider Trades Cardiol Therapeutics Insider Trades Andean Precious Metals Insider Trades Gear Energy Insider Trades Canadian Gold Insider Trades Relevant Gold Insider Trades Ascendant Resources Insider Trades Niobay Metals Insider Trades Galore Resources Insider Trades Pacific Bay Minerals Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles The Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months3 Small Caps Drawing Insider and Institutional Support This page (TSE:MDNA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
